Electromed, Inc. joins the Russell 2000 and Russell 3000 Indexes after strong Q3 earnings. The company’s SmartVest System aids patients with pulmonary conditions. Analysts maintain a Buy rating with a $29 price target. Electromed anticipates 23.66% 5-year EPS growth with a low beta of 0.39.

Freedom Capital Markets initiates coverage of Electromed with a Buy rating. While the company shows potential, other AI stocks may offer greater upside. Electromed, Inc. maintains a stable growth trajectory with promising opportunities. The company is part of a select group of low-risk stocks for long-term investment.

Read more at Yahoo Finance: Electromed Joins Key Indexes Backed By Solid Growth And Stability